STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for STAAR Surgical Company for the period ended June 29, 2001. The company manufactures and markets intraocular lenses (IOLs) and related surgical instruments. The report covers the three and six months ended June 29, 2001, compared to the same periods in 2000.
Key Financial Metrics
| Metric | Six Months Ended June 29, 2001 | Six Months Ended June 30, 2000 |
|---|---|---|
| Total Revenues | $25.9 million | $27.0 million |
| Net Loss | $(4.4) million | $(18.3) million |
| Net Loss Per Share (Diluted) | $(0.26) | $(1.23) |
| Gross Margin | 37.4% | 42.2% |
| Cash and Cash Equivalents | $4.0 million | $3.3 million (beginning of period) |
| Notes Payable (Current) | $9.5 million | $7.9 million |
| Net Working Capital | $17.1 million | $24.3 million |
| Net Cash Used in Operating Activities | $(2.6) million | $(3.0) million |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 4.1% year-over-year for the six-month period, primarily due to discontinued operations in the prior year and unfavorable foreign exchange rates. Sales of Elastic and Elastimide silicone IOLs decreased, partially offset by higher-priced Toric and Collamer IOLs.
- Significant Non-Recurring Charges: The company recorded $5.6 million in charges to cost of sales during the quarter. This included $3.6 million for recalls of the three-piece Collamer IOL and certain silicone IOLs, and $2.0 million for excess and obsolete inventory.
- Improved Loss Position: Net loss improved significantly to $4.4 million from $18.3 million in the prior year. This improvement is largely attributable to the absence of a $13.8 million restructuring charge and a $4.7 million write-off of a Japanese joint venture recorded in the prior year.
- Margin Compression: Gross margin declined to 37.4% from 42.2% due to the aforementioned charges and higher unit costs for silicone IOLs resulting from lower production volumes.
Outlook, Risks, and Management Commentary
- Covenant Waiver: The company was not in compliance with the net income covenant of its $7.0 million line of credit as of June 29, 2001. A waiver was obtained from the lender, and the note maturity was extended to October 1, 2001. Management is seeking alternative financing to pay down or refinance the loan.
- Future Charges: Management announced a new business strategy involving manufacturing consolidation and a global reduction in force of approximately 25%. This is expected to result in fixed asset write-offs and other charges of approximately $5.3 million in the third and fourth quarters of 2001.
- Legal Contingencies: The company is involved in arbitration with its Japanese joint venture partners (Canon, Inc.) regarding alleged breaches of agreement. Additionally, there is ongoing litigation with the former CEO regarding wrongful termination and stock options.
- Product Recalls: A voluntary recall was initiated for the Model CQ-2005V three-piece Collamer IOL due to potential packaging failures affecting sterility. An exchange program was also offered for specific lots of silicone lenses.
Investor Verification Checklist
- Financing Status: Verify the company's success in securing alternative financing to replace the current credit facility before the October 1, 2001 maturity.
- Upcoming Charges: Monitor the impact of the anticipated $5.3 million in restructuring and asset write-offs in the third and fourth quarters of 2001.
- Inventory Management: Assess the effectiveness of inventory reduction strategies following the $2.0 million write-down for excess and obsolete inventory.
- Legal Resolution: Track the status of the arbitration with Canon and the litigation with the former CEO, as these could result in unspecified monetary damages.
- Product Quality: Review the long-term impact of the Collamer IOL recall and silicone lens exchange program on brand reputation and future sales.